Singapore, Oct. 9 -- NEXT&BIO, an affiliate of Kolmar Holdings, has announced the expansion of its research and development (R&D) operations in Singapore. Supported by the Singapore Economic Development Board (EDB), the company will strengthen its local research capabilities, expand its Singapore-based team and deepen its collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS).

NEXT&BIO established an academic joint research laboratory with CSI Singapore at NUS in August 2025, followed by the establishment of its Singapore subsidiary later that year. These operations provide a foundation for the company's translational cancer research, regional business development and co...